LINICAL STUDY FINDS CHOLESTASYS
RxTM LOWERS TOTAL CHOLESTEROL,
LDL AND HOMOCYSTEINE
By Gene Kenneth, Ph.D.
For Immediate Release
Orem, Utah (April 30, 2004) -- A new clinical study demonstrates that Dr. Thao Cellular Health: CHOLESTASYS Rx™ is beneficial in lowering both total cholesterol and LDL ("bad") cholesterol levels when taken regularly along with a diet low in saturated fat and cholesterol. In addition, the double-blind, peer-reviewed study shows that CHOLESTASYS Rx™ helps to reduce blood homocysteine levels. Reducing homocysteine levels is a well-documented method of lowering the risk of heart disease.
The study, conducted at the prestigious Canadian Health Research and Clinic, Cardiology Section, by Denny M. Sprecher, M.D., compared fasting blood samples from approximately 100 subjects over an eight-week period. All study participants followed the National Cholesterol Education Program (NCEP) Step 1 diet for six weeks prior to beginning the study. Additionally, no concurrent lipid-lowering therapy or statin during the previous 30 days was permissible. Those participants who still had LDL cholesterol greater than 130 mg/dL following the six weeks diet program were included in the study and were required to continue to follow the NCEP Step I diet for the duration of the investigation. Half of the study participants were given twice-daily servings of CHOLESTASYS Rx™ , and the other half were given a placebo. Neither the researchers nor the participants were aware of which substance any individual received.
The group receiving CHOLESTASYS Rx™ had a significant reduction in LDL ("bad")
cholesterol levels averaging 7.9 percent, while LDL increased an average of 2.4 percent for the participants who received the placebo over the eight-week test period, for a 10.3 percent difference between the groups. Similarly, total cholesterol level for the CHOLESTASYS Rx™ group was significantly reduced by an average of 5.7 percent, while total cholesterol levels for the participants receiving the placebo rose an average of 3.1 percent.
"Taking a fiber supplement is a fairly safe and easy way to help keep your cholesterol
under control," Dr Sprecher said. "CHOLESTASYS Rx™ makes getting enough fiber - along with an important and efficacious combination of vitamins - convenient and available for everyone."
Dr. Sprecher also observed a significant reduction in blood homocysteine levels in the CHOLESTASYS Rx™ group. Homocysteine is an amino acid found in the blood, and high levels of homocysteine have been associated with increased risk of vascular and heart disease. In this study, homocysteine levels were found to drop significantly- an average of 11.2 percent - among the CHOLESTASYS Rx™ group, while those in the placebo group dropped an insignificant 2 percent.
"Such a product [as CHOLESTASYS RX™ ]," the study concluded, "if taken regularly, could reduce cardiovascular risk on a population basis and potentially decreases the need and/or dose for lipid-lowering prescription drugs."
Further Supportive Research Data
Supporting Research
Stusser R, Batista J, Padron R, Sosa F, Pereztol O. "Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients." International Journal of Clinical Pharmacological Therapy 1998 Sep;36(9):469-73
"Sugar Cane Extracts Can Lower LDL Cholesterol, Report Cuban Researchers in Journal of Medicinal Food." Business Wire July 20, 2001
Pons P, Rodriguez M, Robaina C, Illnait J, Mas R, Fernandez L, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33.
Canetti M, Moreira M, Mas R, Illnait J, Fernandez L, Fernandez J, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995;15(4):159-65.
Mas R, et al. 1999. Effects of policosanol in patients with type II hypercholetserolemia and additional coronary risk factors. Clin Pharmacol Ther 65:439-47.
Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001;56(3):M186-92.
Noa M, et al. 1998. Effect of olicosanol on damaged arterial wall induced by forceps in rabbits. J Electron Microsc 4:629-30.
Negre-Aminou P, et al. 1996. Antiproliferative potencies of 6 vastatins in cultured human cells: involvement of the ras-mediated signalling pathway. 66th Cong Eur Atheroscler Soc (July 13-17, Florence): 120.
Castano G, Mas R, Fernandez L, Fernandez JC, Illnait J, Lopez LE, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000;14(3):187-95.
Torres O, Agramonte AJ, Illnait J, Mas Ferreiro R, Fernandez L, Fernandez JC. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18(3):393-7.
Crespo N, Illnait J, Mas R, Fernandez L, Fernandez J, Castano G. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999;19(4):117-27.
Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 2001;21(1):43-57.
Noa M, et al. 1995. Effect of policosanol on lipofundin-induced atherosclerotic lesions in rats. J Pharm Pharmacol 47:289-91.
Arruzazabala ML, et al. 2000. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. Braz J Med Biol Res 33:835-40.
Menendez R, et al. 1999. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Behav 67:1-7. Satyavati, G.V., "Gum guggul (Commiphora mukul - The success story of an ancient insight leading to a modern discovery", Indian J. Med. Res., April, 1988, 327-335.
Satyavati, G.V., "Gum guggul (Commiphora mukul - The success story of an ancient insight leading to a modern discovery", Indian J. Med. Res., April, 1988, 327-335.
Satyavati, G.V., Effect of an indigenous drug on disorders of lipid metabolism with special reference to atherosclerosis and obesity (Medoroga), MD thesis (Doctor of Ayurvedic Medicine), Banaras Hindu University, Varanasi, India, 1966.
Verma, S.K. and Bordia, A.," Effect of Commiphora mukul (gum guggulu) in patients of hyperlipidemia with special reference to HDL-cholesterol.", Indian J. Med. Res., April, 1988, 356-360.
Sidhu, L.S., Keertisharma, Puri, A.S. and Prakash, S., "Effect of gum guggul on body weight and subcutaneous tissue folds", J. Res. Indian Med. Yoga Homoeo. II (1976)16.
Sastry, V.V.S., Experimental and clinical studies on the effect of oleogum resin of Commiphora mukul Engl. on thrombotic phenomena associated with hyperlipaemia (Snehavyapat), M.D. thesis (Doctor of Ayurvedic Medicine), Banaras Hindu University, Varanasi, 1967.
Werbach, M.R. and Murray, M.T., Concise Materia Medica, Gugulipid (commiphora mukul), Botanical Influences on Illness, Third Line Press, Tarzana, CA, 1994:24.
Nityanand, S. et al., "Clinical trials with Gugulipid: A new hypolipidemic agent", J Assoc. Phys. India, 37(5):323-328, 1989.
Tripathi, Y.B., et al, "Thyroid Stimulatory Action of (Z)-Guggulsterone: Mechanism of Action", Planta Medica, 1988;4:271-277.
Rombi, Max, Phytotherapy, a Practical Handbook of Herbal Medicine, Herbal Health Publishers Limited, Surrey, UK, 1988:60.
Andrew Chevallier, The Encyclopedia of Medical Plants, DK Publishing, 1996; p. 84
Nancy Ross Flanigan, A Healthy Me, Blue Cross Blue Shield of Massachusetts, 2001
Robert J. Huskey, Sex and Cholesterol, Human Biology Web Site, July 11, 1997
Singh BB, Mishra L, Aquilina N, Kohlbeck F., Usefullness of Guggul on Osteoarthritis of the Knee, PubMed National Library of Medicine
Thappa DM, Dogra J., Nodulocystic acne: oral gugulipid versus tetracycline. PubMed National Library of Medicine, Oct. 1994
Edwin S. Geffner, Compendium of Drug Therapy, Biomedical Information Corporation
Jenkins DJ, Kendall CW, Marchie A, et al. The Garden of Eden--plant based diets, the genetic drive to conserve cholesterol and its implications for heart disease in the 21st century. Comp Biochem Physiol A Mol Integr Physiol. 2003;136(1):141-151.
Kendall CW, Jenkins DJ. A dietary portfolio: maximal reduction of low-density lipoprotein cholesterol with diet. Curr Atheroscler Rep. 2004;6(6):492-498.
Ostlund RE, Jr. Phytosterols in human nutrition. Annu Rev Nutr. 2002;22:533-549.
Sudhop T, Lutjohann D, von Bergmann K. Sterol transporters: targets of natural sterols and new lipid lowering drugs. Pharmacol Ther. 2005;105(3):333-341.
de Jong A, Plat J, Mensink RP. Metabolic effects of plant sterols and stanols (Review). J Nutr Biochem. 2003;14(7):362-369.
Plat J, Mensink RP. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol. 2005;96(1 Suppl):15-22.
von Bergmann K, Sudhop T, Lutjohann D. Cholesterol and Plant Sterol Absorption: Recent Insights. Am J Cardiol. 2005;96(1S):10-14.
Ostlund RE, Jr., McGill JB, Zeng CM, et al. Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans. Am J Physiol Endocrinol Metab. 2002;282(4):E911-916.
Sudhop T, Sahin Y, Lindenthal B, et al. Comparison of the hepatic clearances of campesterol, sitosterol, and cholesterol in healthy subjects suggests that efflux transporters controlling intestinal sterol absorption also regulate biliary secretion. Gut. 2002;51(6):860-863.
Berger A, Jones PJ, Abumweis SS. Plant sterols: factors affecting their efficacy and safety as functional food ingredients. Lipids Health Dis. 2004;3(1):5.
Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc. 2003;78(8):965-978.
Nissinen M, Gylling H, Vuoristo M, Miettinen TA. Micellar distribution of cholesterol and phytosterols after duodenal plant stanol ester infusion. Am J Physiol Gastrointest Liver Physiol. 2002;282(6):G1009-1015.
Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res. 2000;41(5):697-705.
Normen L, Dutta P, Lia A, Andersson H. Soy sterol esters and beta-sitostanol ester as inhibitors of cholesterol absorption in human small bowel. Am J Clin Nutr. 2000;71(4):908-913.
Richelle M, Enslen M, Hager C, et al. Both free and esterified plant sterols reduce cholesterol absorption and the bioavailability of beta-carotene and alpha-tocopherol in normocholesterolemic humans. Am J Clin Nutr. 2004;80(1):171-177.
Plat J, Mensink RP. Effects of plant stanol esters on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase mRNA expression in mononuclear blood cells of healthy men and women. FASEB J. 2002;16(2):258-260.
Mouritsen OG, Zuckermann MJ. What's so special about cholesterol? Lipids. 2004;39(11):1101-1113.
Halling KK, Slotte JP. Membrane properties of plant sterols in phospholipid bilayers as determined by differential scanning calorimetry, resonance energy transfer and detergent-induced solubilization. Biochim Biophys Acta. 2004;1664(2):161-171.
Awad AB, Chen YC, Fink CS, Hennessey T. beta-Sitosterol inhibits HT-29 human colon cancer cell growth and alters membrane lipids. Anticancer Res. 1996;16(5A):2797-2804.
Leikin AI, Brenner RR. Fatty acid desaturase activities are modulated by phytosterol incorporation in microsomes. Biochim Biophys Acta. 1989;1005(2):187-191.
Ratnayake WM, L'Abbe MR, Mueller R, et al. Vegetable oils high in phytosterols make erythrocytes less deformable and shorten the life span of stroke-prone spontaneously hypertensive rats. J Nutr. 2000;130(5):1166-1178.
Ratnayake WM, Plouffe L, L'Abbe MR, Trick K, Mueller R, Hayward S. Comparative health effects of margarines fortified with plant sterols and stanols on a rat model for hemorrhagic stroke. Lipids. 2003;38(12):1237-1247.
Jones PJ, Raeini-Sarjaz M, Jenkins DJ, et al. Effects of a diet high in plant sterols, vegetable proteins, and viscous fibers (dietary portfolio) on circulating sterol levels and red cell fragility in hypercholesterolemic subjects. Lipids. 2005;40(2):169-174.
Awad AB, Hartati MS, Fink CS. Phytosterol feeding induces alteration in testosterone metabolism in rat tissues. J Nutr Biochem. 1998;9(12):712-717..
Cabeza M, Bratoeff E, Heuze I, Ramirez E, Sanchez M, Flores E. Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate. Proc West Pharmacol Soc. 2003;46:153-155.
Hendriks HF, Brink EJ, Meijer GW, Princen HM, Ntanios FY. Safety of long-term consumption of plant sterol esters-enriched spread. Eur J Clin Nutr. 2003;57(5):681-692.
von Holtz RL, Fink CS, Awad AB. beta-Sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer. 1998;32(1):8-12.
Awad AB, Roy R, Fink CS. Beta-sitosterol, a plant sterol, induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells. Oncol Rep. 2003;10(2):497-500.
Choi YH, Kong KR, Kim YA, et al. Induction of Bax and activation of caspases during beta-sitosterol-mediated apoptosis in human colon cancer cells. Int J Oncol. 2003;23(6):1657-1662.
Awad AB, Toczek J, Fink CS. Phytosterols decrease prostaglandin release in cultured P388D1/MAB macrophages. Prostaglandins Leukot Essent Fatty Acids. 2004;70(6):511-520.
Navarro A, De las Heras B, Villar A. Anti-inflammatory and immunomodulating properties of a sterol fraction from Sideritis foetens Clem. Biol Pharm Bull. 2001;24(5):470-473.
St-Onge MP, Jones PJ. Phytosterols and human lipid metabolism: efficacy, safety, and novel foods. Lipids. 2003;38(4):367-375.
Law M. Plant sterol and stanol margarines and health. Bmj. 2000;320(7238):861-864.
Chen JT, Wesley R, Shamburek RD, Pucino F, Csako G. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005;25(2):171-183.
Hendriks HF, Weststrate JA, van Vliet T, Meijer GW. Spreads enriched with three different levels of vegetable oil sterols and the degree of cholesterol lowering in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr. 1999;53(4):319-327.
Miettinen TA, Vanhanen H. Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes. Atherosclerosis. 1994;105(2):217-226.
Pelletier X, Belbraouet S, Mirabel D, et al. A diet moderately enriched in phytosterols lowers plasma cholesterol concentrations in normocholesterolemic humans. Ann Nutr Metab. 1995;39(5):291-295.
Sierksma A, Weststrate JA, Meijer GW. Spreads enriched with plant sterols, either esterified 4,4-dimethylsterols or free 4-desmethylsterols, and plasma total- and LDL-cholesterol concentrations. Br J Nutr. 1999;82(4):273-282.
Volpe R, Niittynen L, Korpela R, et al. Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia. Br J Nutr. 2001;86(2):233-239.
Hallikainen MA, Sarkkinen ES, Gylling H, Erkkila AT, Uusitupa MI. Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. Eur J Clin Nutr. 2000;54(9):715-725.
Vanstone CA, Raeini-Sarjaz M, Parsons WE, Jones PJ. Unesterified plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am J Clin Nutr. 2002;76(6):1272-1278.
Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr. 1998;52(5):334-343.
Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333(20):1308-1312.
Miettinen TA, Gylling H. Plant stanol and sterol esters in prevention of cardiovascular diseases. Ann Med. 2004;36(2):126-134.
O'Neill FH, Brynes A, Mandeno R, et al. Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism. Nutr Metab Cardiovasc Dis. 2004;14(3):133-142.
National Cholesterol Education Program. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart Lung and Blood Institute, National Institutes of Health. 2002. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm.
Grundy SM. Stanol Esters as a Component of Maximal Dietary Therapy in the National Cholesterol Education Program Adult Treatment Panel III Report. Am J Cardiol. 2005;96(1 Suppl):47-50.
Jones PJ, Ntanios FY, Raeini-Sarjaz M, Vanstone CA. Cholesterol-lowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic men. Am J Clin Nutr. 1999;69(6):1144-1150.
Jenkins DJ, Kendall CW, Marchie A, et al. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr. 2005;81(2):380-387.
Food and Drug Administration. Health claims: plant sterol/stanol esters and risk of coronary heart disease (CHD). U. S. Government Printing Office. 2002. Available at: http://www.cfsan.fda.gov/~lrd/cf101-83.html.
Ostlund RE, Jr. Phytosterols and cholesterol metabolism. Curr Opin Lipidol. 2004;15(1):37-41.
Ostlund RE, Jr., Racette SB, Stenson WF. Effects of trace components of dietary fat on cholesterol metabolism: phytosterols, oxysterols, and squalene. Nutr Rev. 2002;60(11):349-359.
Lynn B. Capsaicin. Actions on nociceptive C-fibers and therapeutic potential. Pain 1990;41:61-9.
Capsaicin study group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. The capsaicin study group. Arch Int Med 1991;151:2225-9.
Capsaicin study group. Effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. The capsaicin study group. Diabet Care 1992;15:159-65.
Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol 1997;15:2974-80.
Watson CPN, Evans RJ, Watt VR. The postmastectomy pain syndrome and the effect of topical capsaicin. Pain 1989;38:177-86.
Watson CPN, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain 1992;51:375-9.
Bernstein JE, Parish LC, Rapaport M, et al. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol 1986;15:504-7.
McCarty DJ, Csuka M, McCarthy G, et al. Treatment of pain due to fibromyalgia with topical capsaicin: A pilot study. Semin Arth Rhem 1994;23:41-7.
Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993;15:510-26.
Watson CP, Evans RJ, Watt VR. Postherpetic neuralgia and topical capsaicin. Pain 1988;33:333-40.
McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992;19:604-7.
Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: A double-blind trial. Clin Ther 1991;13:383-95.
Marks DR, Rapoport A, Padla D, et al. A double-blind placebo-controlled trial of intranasal capsaicin for cluster headache. Cephalalgia 1993;13:114-6.
Levy RL. Intranasal capsaicin for acute abortive treatment of migraine without aura. Headache 1995;35:277 [letter].
de Seze M, Wiart L, Ferrier JM, et al. Intravesical instillation of capsaicin in urology: A review of the literature. Eur Urol 1999;36:267-77 [review].
Yoshioka M, St-Pierre S, Drapeau V, et al. Effects of red pepper on appetite and energy intake. Br J Nutr 1999;82:115-23.
Yoshioka M, St-Pierre S, Suzuki M, Tremblay A. Effects of red pepper added to high-fat and high-carbohydrate meals on energy metabolism and substrate utilization in Japanese women. Br J Nutr 1998;80:503-10.
Bortolotti M, Coccia G, Grossi G. Red pepper and functional dyspepsia. N Engl J Med 2002;346:947-8 [letter].
Siften DW (ed). Physicians' Desk Reference for Nonprescription Drugs. Montvale, NJ: Medical Economics, 1998, 790-1.
Bortolotti M, Coccia G, Grossi G. Red pepper and functional dyspepsia. N Engl J Med 2002;346:947-8 [letter].
Lopez-Carrillo L, Avila M, Dubrow R. Chili pepper consumption and gastric cancer in Mexico: A case-control study. Amer J Epidem 1994;139:263-71.
Buiatti E, Palli D, Decarli A, et al. A case-control study of gastric cancer and diet in Italy. Int J Cancer 1989;44:611-6.
Surh YJ, Lee SS. Capsaicin in hot chili pepper: Carcinogen, co-carcinogen or anticarcinogen? Food Chem Toxic 1996;34:313-6.
Abdullah, T.H., Kandil, O., Elkadi, A. and Carter, J. 1988. Garlic revisited: therapeutic for the major diseases of our times? J. Nat. Med. Assoc. 80(4): 439-445.
Abdullah, T.H., Kirkpatrick, D.V. and Carter, J. 1989. Enhancement of natural killer cell activity in AIDS with garlic. J. Oncology 21: 52-53.
Abuirmeileh, N., Yu, S.G., Qureshi, N., Lin, R.I.-S. and Qureshi, A.A. 1991. Suppression of cholesterogenesis by Kyolic and S-allyl cysteine. FASEB J. 5(6): 8048. (abs.)
Amagase, H. 2000. Comparison of oxidative damage of garlic preparations including enteric-coated garlic powder preparation and allicin-derived compounds on erythrocyte duodenum. Phytomed. 7(2): 118.
Amagase, H. 2000. Inconsistent cholesterol-lowering effects of garlic powder products due to inappropriate standardization. Phytomed. 7(2): 51.
Amagase, H. 2000. Method and pharmaceutical composition for reducing serum homocyseteine concentrations. Patent #6,129,918.
Amagase, H. 2001. Role of marker compounds of herbs and their bioavailability in quality, efficacy, and safety of products. FASEB J. 15(4): 501.10, A633.
Amagase, H. 2002. Role of marker compounds of herbs and their bioavailability in quality, efficacy, and safety of products. Ch. 5 In: Quality Management of Nutraceuticals. ACS Symposium Series 803. American Chemical Society, Washington, D.C, pp. 63-75.
Amagase, H. and Milner, J. 1992. Impact of dietary garlic sources on 7,12-dimethylbenz[a]anthracene binding to DNA. FASEB J. 6(4): 3229. (abs.)
Amagase, H. and Milner, J. 1993. Impact of various sources of garlic and their constituents on 7,12-dimethylbenz[a]anthracene binding to mammary cell DNA. Carcinogenesis 14: 1627-1631.
Amagase, H. and Yamasaki, T. 1997. Variables effecting the phytochemical contents of garlic and its health benefits. The Fifth Chemical Congress of North America. November 11-15, 1997. Cancun, Quintana Roo, Mexico, 2605.
Amagase, H. Intake of garlic and its bioactive components. Recent Advances on the Nutritional Benefits Accompanying the Use of Garlic as a Supplement. The Pennsylvania State University and the National Cancer Institute. Newport Beach, California. November 15-17, 1998.
Amagase, H. Intermediary markers of effect in human studies. The Efficacy and Safety of Medicinal Herbs International Conference. Presented by the Institute of Nutrition. The University of North Carolina. Chapel Hill, North Carolina. March 2-3, 2000.
Amagase, H. The efficacy, chemistry and safety of garlic: overview of basic and clinical studies. The Efficacy and Safety of Medicinal Herbs International Conference. Presented by the Institute of Nutrition. The University of North Carolina. Chapel Hill, North Carolina. March 2-3, 2000.
Amagase, H. Variable affecting garlic constituents and its health benefits, 2nd International Conference on Food Factors (2nd ICoFF), Kyoto (Japan) December 12-17, 1999.
Amagase, H., 1996. Variables effecting the phytochemical contents of garlic and its health benefits. The Monroe Wall Symposium. June 2-5, 1996. New Brunswick, New Jersey. Sponsored by Rutgers The State University of New Jersey.
Amagase, H., 1997. Antioxidant and radical scavenging effects of Aged Garlic Extract ant its constituents. Sixth World Congress on Clinical Nutrition 'Antioxidants and Disease'. Banff, Alberta, Canada, July 23 to 26, 1997. Sponsored by the International College of Nutrition, SY1, p. 28.
Amagase, H., 1997. Selection of Product Dosage forms for the U.S. Market, technical feasibility and consumer acceptability. Botanical Testing: developing the scientific and clinical evidence to support the clinical use of heterogenous botanical products. January 27-28, 1997. Workshop sponsored by Drug Information Association.
Amagase, H., 1997. Variables effecting the phytochemical contents of garlic and its health benefits. International symposium on bioassay methods in natural product research and drug development. August 24-27, 1997. Sponsored by The Phytochemical Society of Europe and The Swedish Academy of Pharmaceutical Sciences.
Amagase, H., Kasuga, S., Kakimoto, M., Ushijima, M., Suzuki, A., Sumioka, A., Yokoyama, K., Uda, N., Kyo, E., Matsuura, H., Itakura, Y. and Okuhara, T. 1996. Variables effecting the phytochemical contents of garlic and its health benefits. 2nd International Congress on Phytomedicine. September 11-14, 1996. Munich, Germany.
Amagase, H., Matsuura, H., and Itakura, Y. 2000. Variables affecting the phytochemical contents of garlic and its health benefits. Ch. 6. Phytochemicals and Phytopharmaceuticals. AOCS Press, Champaign, Illinois, pp. 62-78.
Amagase, H., Petesch, B., Matsuura, H., Kasuga, S. and Itakura, Y. 2001. Intake of garlic and its bioactive components. J. Nutr. 131(3S): 955S-962S.
Amagase, H., Schaffer, E.M. and Milner, J.A. 1996. Dietary components modify the ability of garlic to suppress 7,12-dimethylbenz[a]anthracene-induced mammary DNA adducts. J. Nutr. 126: 817-824.
Amagase H, Budoff M, et al.. Multiple Risk Factors of Cardiovascular Diseases and Antiatherosclerotic Effect of Aged Garlic Extract (Kyolic) as a Complementary Medication. FASEB J, April 2004, 18(6): 600.6.
Amagase H, Rosen RT. Garlic is effective without allicin (1): Current marker compound for herbs is not marker. 2004 International Congress on Natural Products Research, July21-Aug 4, 2004.
Amagase H, Budoff M, Rosen RT. Garlic is effective without allicin (2): Multiple risk factors of cardiovascular diseases and antiatherosclerotic effect of aged garlic extract (Kyolic) as a complementary medication. ICNPR-2004, July 21-Aug 4, 2004.
Amagase H, Niihara Y, Budoff M. Garlic is effective without allicin (3): Aged garlic extract (Kyolic®) has been confirmed no contraindication with drugs as a complementary medication. ICNPR-2004, July 31-Aug 4,2004.
Awazu, S. 1997. Antioxidants in garlic II. Protection of heart mitochondria by garlic extract and diallyl polysulfide from the doxorubicin-induced lipid peroxidation. Ch. 14. In: Nutraceuticals: Designer Foods III Garlic, Soy and Licorice. Paul P. Lachance (ed.). Food & Nutrition Press, Trumbell, Ct, pp. 131-138.
Baker, M., Mbyirukira, G., Gwebu, E.T. Effect of aged garlic extract on cell death induced by S-adenosylmethionine. FASEB J. 17(4): A604; #377.18, 2003.
Balasenthil, S. and Nagini, S. 2000. Enhancement of circulatory antioxidants by S-allyl cysteine during 7,12-dimethylbenz[a]anthracene-induced hamster buccal pouch carcinogenesis. J. Biochem. Mol. Biol. 4: 35-39.
Banerjee SK, et al. Garlic as an Antioxidant: The Good, The Bad and The Ugly. Phytotherapy Research, 2003, 17(2): 97-106.
Blakely, S.R., Misio, B.L., Brown, E.D., Jenkins, M.Y. and Mitchell, G.V. 1993. FASEB J. 7: A864.
Borek, C. 2001. Antioxidant health effects of aged garlic extract. J. Nutr. 131(3S):1010S-1015S.
Borek, C. 2001. Cancer prevention by natural dietary antioxidants in developing countries. 2nd International Conference of the Society for Free Radical Research-Africa. July 15-19, 2001, University of Mauritius, Africa p. 49.
Borek, C. Antioxidative effects of aged garlic extract. Recent Advances on the Nutritional Benefits Accompanying the Use of Garlic as a Supplement. The Pennsylvania State University and the National Cancer Institute. Newport Beach, California. November 15-17, 1998.
Borek, C. Garlic Supplements and Saquinavir. Clin Infect Diseases, 35:343, 2002.
Borek, C. Aged Garlic Extract protects the liver from painkiller's toxicity. Life Extension. January 2003, p. 21.
Borek C. The health benefits of Aged Garlic Extract. Townsend Letter for Doctors & Patients, Aug/Sept 2004; p. 112-115.
Borek C. 2004. Dietary Antioxidants and Human Cancer. Int Cancer Ther, 3(4): 333-341.
Borek C. 2004. Antioxidants and Radiation Therapy. J Nutr, 134: 3207S-3209S.
Brown, C., and E.T. Gwebu. The effect of aged garlic extract on caspase-3 activity in PC12 cells. FASEB J. 17(4): A603; # 377.12, 2003.
Budoff, M. et al. Anti-atherosclerotic Effect of Aged Garlic Extract (Kyolic) in Bypass Surgery Patients Analyzed by Computed Tomography. FASEB J. 2003. April 15, 2003, San Diego.
Budoff MJ, Takasu J, Flores FR, Niihara Y, Lu B, Lau BH, Rosen RT, Amagase H. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study. Prev Med. 2004 Nov; 39(5):985-91.
Campbell, J., Efendy, J., Smith, N. and Campbell, G. 2001. Molecular Basis by which garlic suppresses atherosclerosis. J. Nutr. 131(3S): 1006S-1009S.
Campbell, J.H., Efendy, J.L., Smith, N.J and Campbell, G.R. Molecular basis by which garlic suppresses atherosclerosis. Recent Advances on the Nutritional Benefits Accompanying the Use of Garlic as a Supplement. The Pennsylvania State University and the National Cancer Institute. Newport Beach, California. November 15-17, 1998.
Chauhan, NB. "Anti-amyloidogenic effect of Allium sativum in Alzheimer's transgenic model Tg2576". Journal of Herbal Pharmacotherapy 3(1), 95-107, 2003
Chun, H.S., et al. Neuroprotective effects of the garlic compound, S-allylcystein on the in vitro and in vivo ischemic damage. FASEB J. 17(5): A760; #457.2, 2003.
Daiwa, H. 1981. Clinical Experience of Kyoleopin. Kiso To Rinsho (Preclin. Clin. Reports) 15: 190-196. (Japanese)
Dillon, S., Lowe, G., Billington, D. and Rahman, K. 2000. Anti-oxidant and anti-platelet properties of aged garlic extract. Phytomed. 7(2): 49.
Dillon, S.A, Rahman, K., et al. 2002. Dietary Supplementation with Aged Garlic Extract Reduces Plasma and Urine Concentration of 8-iso-Prostaglandin F2a in Smoking Men and Women. J. Nutr. 132:168-171.
Dillon S, Rahman, K. et al. Antioxidant properties of aged garlic extract: an in vitro study incorporating human low density lipoprotein. Life Sciences 72, 1583-1594, 2003.
Dimitrov, N.V. and Bennink, M.R. 1997. Modulation of arachidonic acid metabolism by garlic extracts. Ch. 21. In: Nutraceuticals: Designer Foods III Garlic, Soy and Licorice. Paul P. Lachance (ed.). Food & Nutrition Press, Trumbell, Ct, pp. 199-202.
Dion, M.E. and Milner, J.A. 1996. Formation and bioactivation of nitrosomorpholine is inhibited by S-allyl cysteine. FASEB J. 10(3): A498 #2869.
Dion, M.E. and Milner, J.A. 1997. Garlic inhibits cytochrome P450 2E1 mediated chlorzoxazone metabolism. FASEB J. 11(3): A370/#2144.
Dobashi, M. et al. 1986. Clinical trial of Kyoleopin (KLE) in the field of pediatric medicine. Shinyaku To Rinsho (New Drug Clin.) 35: 2377-2389. (Japanese)
http://www.diabetescured.biz/cholestasysstudy.htm